

Distinct roles of Pcf11 zinc-binding domains in pre-mRNA 3'-end processing

Julia Guéguénat^{1,†}, Adrien F. Dupin^{1,†}, Johan Stojko², Lionel Beaupaire¹, Sarah Cianférani², Cameron D. Mackereth^{1,*}, Lionel Minvielle-Sébastien^{1,*} and Sébastien Fribourg^{1,*}

¹Université de Bordeaux, INSERM U1212, CNRS UMR5320, Bordeaux, France and ²Laboratoire de Spectrométrie de Masse BioOrganique, Université de Strasbourg, CNRS, IPHC UMR 7178, 67000 Strasbourg, France

Received February 01, 2017; Revised July 18, 2017; Editorial Decision July 20, 2017; Accepted July 21, 2017

ABSTRACT

New transcripts generated by RNA polymerase II (RNAPII) are generally processed in order to form mature mRNAs. Two key processing steps include a precise cleavage within the 3' end of the pre-mRNA, and the subsequent polymerization of adenosines to produce the poly(A) tail. In yeast, these two functions are performed by a large multi-subunit complex that includes the Cleavage Factor IA (CF IA). The four proteins Pcf11, Clp1, Rna14 and Rna15 constitute the yeast CF IA, and of these, Pcf11 is structurally the least characterized. Here, we provide evidence for the binding of two Zn²⁺ atoms to Pcf11, bound to separate zinc-binding domains located on each side of the Clp1 recognition region. Additional structural characterization of the second zinc-binding domain shows that it forms an unusual zinc finger fold. We further demonstrate that the two domains are not mandatory for CF IA assembly nor RNA polymerase II transcription termination, but are rather involved to different extents in the pre-mRNA 3'-end processing mechanism. Our data thus contribute to a more complete understanding of the architecture and function of Pcf11 and its role within the yeast CF IA complex.

INTRODUCTION

Polyadenylation of mRNA 3'-ends is a co-transcriptional event that occurs for nearly all eukaryotic mRNA with the exception of histone mRNAs (1). This process relies on a two-step mechanism starting with cleavage of the pre-mRNA in the 3'-untranslated region (3'-UTR) (2–4). This first step is immediately followed by the polymer-

ization of adenosines at the 3'-hydroxyl end of the upstream cleavage product, while the downstream fragment is degraded by Rat1 (5). In yeast, the polyadenylation machinery comprises two large multi-protein complexes: the Cleavage/polyadenylation Factor IA (CF IA) (6,7) and the Cleavage and Polyadenylation Factor (CPF). Additional factors are also required for the *in vitro* process such as Hrp1/Nab4 (6,8) and the poly(A)-binding proteins Pab1 and Nab2 (7,9–11).

The CF IA complex consists of the four proteins Rna14, Rna15, Pcf11 and Clp1. Each of these proteins consists of distinct domains that contribute to the function of CF IA, including assembly of the complex and interaction with other components of the processing machinery or target pre-mRNA. Investigation of these structured domains has directly led to insight into CF IA architecture and function. Solution studies and crystal structures of the *Kluyveromyces lactis* Rna14, as well as the orthologue CstF-77 from *Encephalitozoon cuniculi* and *Mus musculus*, have shown that Rna14 and CstF-77 self-associate into tight homodimers (12–15). The C-terminal region of Rna14 also forms a heteromeric complex with Rna15 as revealed by the solution structure of the Rna14–Rna15 minimal heterodimer (16) and the structure of the Rna14–Rna15 sub-complex from *K. lactis* (15). A three-helix bundle at the C-terminus of Rna15 has been shown to contact Pcf11 (17), and a short region in Pcf11 mediates association with Clp1 as observed in the structure of a Clp1–Pcf11 minimal complex (18,19). These contacts contribute to the correct assembly of CF IA, although they also dictate a more complicated stoichiometry versus a simple heterotetramer (20). Recent studies have proposed an overall model for CF IA (21), with a stoichiometry of 2:2:1:1 or 2:1:1:1 (21,22) respectively for Rna14:Rna15:Clp1:Pcf11, but the functional basis for such an asymmetry has not yet been described.

*To whom correspondence should be addressed. Tel: +33 557 571 511; Fax: +33 557 571 015; Email: sebastien.fribourg@inserm.fr
Correspondence may also be addressed to Lionel Minvielle-Sébastien. Tel: +33 557 574 601; Fax: +33 557 571 015; Email: lionel.minvielle-sebastia@inserm.fr
Correspondence may also be addressed to Cameron D. Mackereth. Tel: +33 540 003 432; Fax: +33 540 003 004; Email: cameron.mackereth@inserm.fr

†These authors contributed equally to this work as first authors.

Present address: Julia Guéguénat, Department of Molecular Genetics, The Ohio State University, Columbus, OH 43210, USA.

Protein domains within CF IA also enable interaction with the target pre-mRNA and components of the transcription and processing machinery. Molecular characterization of the RNA recognition motif (RRM) domain of Rna15, and the orthologue CstF-64, reveal aspects of pre-mRNA binding (23). Increased RNA sequence specificity has also been demonstrated with structural details of the auxiliary subunit Hrp1 (also known as CF IB or Nab4), and in particular within a Hrp1–Rna15–RNA ternary complex (24–26). A connection to the largest subunit of RNA polymerase II, Rpb1 is mediated by the C-terminal interacting domain (CID) of Pcf11 that binds to the Rpb1 C-terminal YSPTSPS heptamer repeats with phosphorylation on the serine in position 2 (27,28).

Despite the characterization of the CF IA domains described above, additional folded domains remain to be studied. This is most evident for Pcf11, for which only the N-terminal CID, the short Clp1-interacting region and recently, a zinc-binding domain (29) are described at the atomic level. In this study, we have analysed additional regions of Pcf11 and demonstrated that Pcf11 has two zinc-binding domains. Interestingly, mutations of these domains affect Pcf11 function to different extents. Mutation of the C-terminal zinc-binding motif has a dramatic impact on both yeast viability and pre-mRNA 3'-end processing, whereas mutations in the upstream zinc-binding domain has a small but noticeable effect on cell growth and 3'-end formation, suggesting different functions of these potentially similar motifs. The entire zinc finger region of Pcf11 is also capable of a non-specific interaction with RNA but only in the absence of Clp1. The C-terminal zinc-binding domain, which we find essential for pre-mRNA 3'-end processing, was also produced in isolation and was shown to contain flexible residues around an unusual zinc-binding fold. Altogether, this study provides a refined description of Pcf11 organization and gives novel insights into CF IA in mRNA 3'-end maturation.

MATERIALS AND METHODS

Cloning and rCF IA complex expression

Each full-length protein was obtained by PCR on yeast *Saccharomyces cerevisiae* genome and cloned into modified versions of pET-15b, pET28b, pCDF and pLysS bacterial expression plasmids (30,31). Integrity of each clone was verified by sequencing. For co-expression, BL21(DE3) (Novagen) were transformed with the relevant combination of plasmids and plated on Petri dishes with half of the recommended antibiotic concentration. Mini-cultures were grown in 10 ml of LB at 37°C with antibiotics and protein expression was induced by addition of a final concentration of 1 mM IPTG and overnight incubation at 15°C. Cells were harvested by centrifugation and lysed by sonication with buffer containing 1.5x PBS, 1 mM Mg(OAc)₂, 0.1% NP-40, 20 mM imidazole, 10% (w/v) glycerol. After centrifugation, the supernatant was incubated with His-affinity resin (Sigma) for 30 min at 4°C. The resin was extensively washed and bound proteins were analysed by SDS-PAGE after addition of loading buffer.

Pull-down assays

After overnight induction of 10 ml culture with 0.1 mM IPTG, harvested cells resuspended in lysis buffer (1.5x PBS, 1 mM Mg(OAc)₂, 0.1% NP-40, 20 mM Imidazole, 10% (w/v) glycerol) were lysed by 10 s sonication at 3 W. Crude extract was then centrifuged and soluble fraction incubated 30 min with 30 µl of His-Affinity Cobalt resin. After three washing steps with 1 ml of lysis buffer, beads were eluted with 3 volumes of lysis buffer supplemented with 250 mM imidazole and one-third of the sample was loaded on a SDS-polyacrylamide gel.

rCF IA complex purification

For large-scale protein purification, the plasmids expressing Pcf11 deleted from the residues 234 to 253 fused to a N-terminal His-tag, as well as a tri-cistronic construct encoding Rna15, Rna14 and Clp1 were transformed into *Escherichia coli* BL21 Rosetta 2 (DE3) cells. Two liters of Terrific Broth (TB) were inoculated with the relevant overnight pre-culture and grown to an OD of 1.5 and induced by addition of a final concentration of 1 mM IPTG and overnight incubation at 15°C. After cell harvesting, the cell pellet was resuspended in a buffer containing 25 mM Tris–HCl pH 7.5, 150 mM NaCl and lysed by three passes into an EmulsiFlex C3 (Avestin). The crude extract was centrifuged at 50 000 g for 1 h at 4°C. The supernatant was incubated with His-affinity resin (Sigma) and loaded onto an AK 16 column (GE Healthcare). Contaminants were removed by extensive wash with buffer A containing 25 mM Tris–HCl pH 7.5, 150 mM NaCl. Proteins were eluted from the column with a gradient of buffer A supplemented with 250 mM imidazole. The eluted proteins were then loaded onto a HP-Heparin 5 ml (GE Healthcare) and separated by a gradient of NaCl up to 500 mM in 25 mM Tris–HCl pH 7.5. The pool of fractions was concentrated and loaded onto a Superdex-200pg column (GE Healthcare) equilibrated in 25 mM Tris–HCl pH 7.5, 250 mM NaCl, 1 mM DTT.

Zinc-binding domains purification

The DNA sequence coding for residues 530–626 or 403–626 of Pcf11 were cloned into a modified pET-15b plasmid allowing the production of an N-terminally His₆-GST-tagged proteins. The plasmids were transformed into *E. coli* BL21 (DE3). For large-scale protein purification, 1 L of TB was inoculated with the relevant overnight pre-culture and grown up to an OD of 1.5. After cell harvesting, the cell pellet was resuspended in a buffer containing 25 mM Tris–HCl pH 7.5, 150 mM and lysed by three passes into an EmulsiFlex C3 (Avestin). The crude extract was centrifuged at 50 000 g for 1 h at 4°C. The supernatant was incubated with His-affinity resin (Sigma) and loaded onto an AK 16 column (GE Healthcare). Contaminants were removed by extensive washes with a buffer A containing 25 mM Tris–HCl pH 7.5, 250 mM NaCl. Proteins were eluted from the column with a gradient of imidazole up to 250 mM supplemented in buffer A. The eluted proteins were cleaved with Tev protease to remove the His-GST tag over-night at 4°C. Then a Hi-prep 26/10 Desalting column was used to exchange the protein buffer into the Buffer A. The protein was

then loaded on a His-affinity column to eliminate the His-GST tag and Tev protease. The zinc-finger domain was further purified using a High-resolution Superdex S-75pg gel-filtration column (GE Healthcare) equilibrated in 50 mM Tris (pH 7.5), 150 mM NaCl supplemented with 50 μ M Zn(OAc)₂. The purified protein samples were concentrated to 2.6 mg ml⁻¹, frozen and stored at -80°C. The concentration was estimated from absorbance at 280 nm assuming absorption of 1.54 cm⁻¹ for a 1 mg ml⁻¹ solution as calculated from the construct sequence.

NMR spectroscopy

In addition to protein expressed in LB media at natural abundance, GST-tagged Pcf11 (530–626) was also expressed by using Rosetta2 (DE3) cells in M9 minimal media supplemented with 1 g/l [¹⁵N]-ammonium chloride, 2 g/l [¹³C]-glucose or with 2 g/l [10%-¹³C]-glucose and purified as with the natural abundance protein. Purified samples contained 100–360 μ M untagged protein in 50 mM Tris (pH 7.5), 150 mM NaCl, 50 μ M Zn(OAc)₂ with either 10% or 99% (v/v) ²H₂O. NMR spectra were acquired at 20°C on a 700 MHz or 800 MHz Bruker Avance III spectrometer, equipped with a room temperature or cryogenic triple resonance gradient probe, respectively. Data acquisition used TopSpin versions 2.1 and 3.2. Processing used NMRPipe/NMRDraw (32) and data analysis used Sparky (T.D. Goddard & D. G. Kneller, University of California, San Francisco, USA). Chemical shift assignment of the backbone ¹H, ¹³C and ¹⁵N nuclei of Pcf11 for residues 548–603 relied on 2D ¹H,¹⁵N-HSQC, 3D HNCO, 3D HNCACO, 3D HNCA, 3D CBCA(CO)NH, 3D HNCACB and 3D HNHA spectra. Aliphatic sidechain assignment used 2D ¹³C-HSQC, 3D (H)CCONH-TOCSY (14 ms mixing time), H(C)CH-TOCSY (14 ms mixing time) (H)CCH-TOCSY (14 ms mixing time). Stereospecific assignment of the γ 1/ γ 2 methyl groups of valine and the δ 1/ δ 2 methyl groups of leucine used the sample prepared with [10%-¹³C]-glucose (33). Aromatic sidechain assignment used 2D ¹H,¹³C-HSQC and ¹H,¹⁵N-NOESY (150 ms mixing time) spectra, with an additional long-range ¹H,¹⁵N-HMBC spectrum to determine the protonation state of the δ 1 and ϵ 2 nitrogen atoms of the two histidine residues. The ¹H, ¹³C and ¹⁵N chemical shift assignments have been deposited in the Biomolecular Magnetic Resonance Data Bank (<http://bmr.b.wisc.edu>) under accession code 34061.

Structure calculation

The backbone ¹H^N, ¹H α , ¹³C α , ¹³C β , ¹³C γ and ¹⁵N^H chemical shift values of Pcf11 (530–626) provided Ψ and Φ angular restraints for 51 residues by using TALOS-N (34). In addition, 30 χ 1 angular restraints were obtained. Two additional χ angle restraints for Val552 and Ile588 were based on analysis of ¹³C side chain resonances and the program Sider (35,36). Distance restraints were obtained from 2D ¹H,¹H-NOESY (150 ms mixing time), 3D ¹H,¹H-NOESY-¹³C-HMQC (150 ms mixing time) and 3D ¹H,¹⁵N-HSQC-¹H-NOESY (150 ms mixing time) with an initial set of 976, 701 and 338 crosspeaks, respectively. The final list of

unambiguous restraints included 353 intraresidue, 160 sequential, 54 medium and 332 long range distances, with an additional list of 271 ambiguous distance restraints. The four distance and 13 dihedral zinc-binding geometry constraints were excluded from the initial structure calculation, and were only incorporated in the final annealing step performed in explicit water. The final ensemble contains the 15 lowest energy structures calculated by using CNS1.1 (37) implemented within ARIA1.2 (38). The structure ensemble has been deposited in the Protein Data Bank (<http://www.ebi.ac.uk/pdbe>) with PDB ID 5M9Z.

Atomic absorption spectroscopy

Protein samples were dialyzed against 20 mM Tris-HCl pH 8, 250 mM NaCl, 5 mM 2-mercaptoethanol, 0.1 mM EDTA at 4°C for 16 h. Measurement of metal content was performed on a Varian AA75 spectrophotometer at the appropriate wavelength and deduced from a standard calibration.

Mass spectrometry experiments

Pcf11 (530–626) constructs and Clp1-Pcf11 (403-626) sub-complexes were first buffer exchanged against a 250 mM ammonium acetate (NH₄Ac) solution at pH 7.5 using gel filtration (Zeba 0.5 ml, Thermo Scientific, Rockford, IL, USA) and ultrafiltration spin columns (Vivaspin 500 MWCO 10 000, Sartorius, Göttingen, DE), respectively. Protein concentration was determined spectrophotometrically. NanoESI-MS characterization of Pcf11 variants was next generated on an electrospray TOF mass spectrometer (LCT, Waters, Manchester, UK) and on a Q-TOF (Synapt G2 HDMS, Waters, Manchester, UK), both equipped with an automated chip-based nanoESI source (Triversa Nanomate, Advion Biosciences, Ithaca, NY, USA) operating in the positive ion mode. External calibrations were generated from the multiple charged ions produced by a 2 μ M horse heart myoglobin solution diluted in a 1:1 (v/v) water: acetonitrile mixture acidified with 1% (v/v) formic acid, and caesium iodide clusters diluted to 2 g/l in a 1:1 (v/v) water: isopropanol solution. Intact masses of individual Pcf11 constructs were first determined in denaturing conditions by diluting proteins to 2 μ M in a 1:1 (v/v) water/acetonitrile mixture acidified with 1% (v/v) formic acid. Non-covalent complexes analysis in non-denaturing conditions was then performed by diluting samples to 5 μ M in 250 mM NH₄Ac buffer at pH 7.5. Fine-tuning of instrumental parameters was notably applied to preserve non-covalently bound species in the gas phase and ensure efficient ion transmission. Particularly, LCT and Synapt G2 source back pressures were respectively raised to 6.7 and 7.7 mbar using a throttling valve, while acceleration voltages applied on the sample cone were set to 120 and 80 V. Data processing was finally carried out on MassLynx 4.0 (Waters, Manchester, UK).

Purification and analysis of yeast 3'-end processing factors

Yeast extracts were prepared following the spheroplast procedure and tandem-affinity purification (TAP) of the factors was performed as described previously (10). The immunoblot analysis of 3' processing complexes was done

with equal amounts of purified factors run on 12% polyacrylamide-SDS gels and probed after transfer with rabbit polyclonal antibodies to Rna14 (1:3000), Rna15 (1:10000), Pcf11 (1:2000) and Clp1 (1:1000).

In vitro pre-mRNA 3'-end processing assays

Pre-mRNA 3'-end processing assays were performed with purified factors as described previously on the *CYCI* or *CYCI* pre-cleaved (*CYC1pre*) precursors radiolabeled *in vitro* with α -³²P-UTP (10,39). Native CF IA (nCF IA) and nCPF were purified from yeast cells according to the TAP procedure (40) from strains expressing N-terminal TAP-tagged *RNAI5* and TAP-tagged *FIP1*, respectively (see Table 3 for the strains). The purification of nCPF was performed in a *rna15-1* mutant background (inactive in this mutant form (39)) to ensure that no active nCF IA copurifies and obscures the complementation assays with CF IA coming from native or recombinant origins (Figures 2 and 7). Hrp1/Nab4 (50 ng per assay) and Pab1 (140 ng per assay) were obtained from recombinant sources (10). Recombinant CF IA (rCF IA- ΔQ_{20}) was obtained as described above. Reaction products of processing assays were analyzed on 6% polyacrylamide–8.3 M urea gels and visualized by phosphorimaging.

Yeast strains and plasmids

Strain YLM232 containing the *pcf11* Δ ::*HIS3* allele was constructed by replacing the *TRP1* marker disrupting the *PCF11* gene in strain NA50 (41) by the *HIS3* marker. All of the yeast strains used in this study are listed in Table 3. pNA39 (*URA3-ARS/CEN-AmpR* (41)) was used to complement the *pcf11* Δ ::*HIS3* null allele in YLM233 strain. The *PCF11* gene was also amplified by PCR with *S. cerevisiae* genomic DNA as template, from position –458 to +2566 (nucleotide +1 corresponding to the A of the start codon of *PCF11* open reading frame) and cloned into the pFL36 Δ SX plasmid (*LEU2-ARS/CEN-AmpR*); this plasmid was constructed as described in (41). Mutations of the two zinc-binding domains were obtained by site-directed mutagenesis and re-introduced in pFL36 or pFL36 Δ SX by gap-repair in yeast (for *pcf11-18*) or by direct cloning (for *pcf11-19*), respectively. Plasmid pFL36 Δ SX-*pcf11*- ΔQ_{20} was constructed by gap-repair. All of the constructs were verified by sequencing. Haploid strains expressing wild-type (YLM244) or mutant (YJG23, YJG24) plasmid-borne *PCF11* alleles together with the TAP-tagged *RNAI5* gene were obtained by crossing YLM237, YJG10 and YJG12 with YLM221, respectively (see Table 3), and analysis of their progeny after meiosis. Mutant *pcf11-20* expressing the Pcf11 protein mutated in the two zinc-binding domains was cloned in pFL36 Δ SX and used to transform the diploid strain YLM232. Phenotypic analysis of the progeny after meiosis is described in Figure 1C.

S1 nuclease protection assay

Plasmids used for the S1 nuclease protection assays were made as follows: a PCR fragment encompassing the sequence ranging from the *Xho* I site located at nucleotide +45

(according to the start of mature snR13 RNA) to nucleotide +93 in the *TRS31* gene (+1 being the start of *TRS31* ORF) was amplified from yeast genomic DNA and cloned into the pGEM4 vector between the *EcoR* I and *BamH* I restriction sites (Promega). This plasmid was digested with *Xho* I and *Pvu* II, the released fragment was purified on an agarose gel and 3'-end labeled with the Klenow enzyme and [α -³²P]-TTP (25 μ Ci/3000 Ci/mmol). Approximately 30 ng of the labeled DNA probe were hybridized with 30 μ g of total RNAs extracted from each strain or 2 μ g of control yeast tRNA and digested with 150 units of S1 nuclease (42). The protected fragments were resolved on 8% polyacrylamide–8.3 M urea gels and analyzed by phosphorimaging. The positive control RNA was obtained from a PCR fragment covering the whole snR13 mature transcription unit down to nucleotide +291 cloned between the *EcoR* I and *Hind* III restriction sites of pGEM4. The resulting plasmid was cut with *EcoR* I and served as template for the generation of a synthetic RNA by run-off transcription with T7 RNA polymerase.

UV-crosslinking assay

UV cross-linking reactions were performed in microtiter plates and contained (in 10 μ l) 100 fmol of ³²P-labeled *CYCI* in 75 mM potassium acetate, 2 mM magnesium acetate, 0.01% NP-40, 1 mM DTT, 0.1 mg/ml purified BSA, 2 μ M tRNA (0.5 μ g), 5 μ g total yeast RNA (when applicable) and 100 ng of recombinant proteins. The proteins were first incubated for 15 min at 30°C in the reaction mixture either alone or in the presence of 5 μ g of total yeast RNA. The *in vitro*-labeled *CYCI* transcript was then added and the incubation was further continued for 15 min at 30°C. The samples were irradiated twice at 500 mJ on ice in a UV Stratalinker, and then digested with RNase A (100 ng per reaction) for 30 min at 37°C. The proteins were mixed with 3 μ l of SDS-loading buffer and separated on SDS–12% polyacrylamide gels. The gels were fixed, dried and visualized by phosphorimaging. To control that equal amounts of the different versions of the recombinant Pcf11^[403–626] polypeptides were used for UV cross-linking, ~600 ng of each recombinant proteins was loaded on a SDS–12% polyacrylamide gel and the proteins were compared after Coomassie staining (see Figure 9A).

RESULTS

Putative zinc-binding domains in Pcf11 are required for cell viability

Sequence analyses of the yeast Pcf11 protein have previously revealed the presence of two zinc-finger motifs of the C₂H₂ and CCHC types neighboring the Clp1 interaction domain (Figure 1A; Supplementary Figure S1) (29,43,44). As a step towards experimental confirmation, we analysed whether these putative zinc-binding residues are important for cell viability. To do so, the *PCF11* gene under its natural promoter was amplified by PCR and cloned into pFL36 and pFL38 centromeric plasmids. We next introduced point mutations in the *PCF11* gene to target two potential zinc-binding residues within each region. Specifically, the conserved C421 and C424 residues within the first




Figure 1. Effect of mutations of the Pcf11 zinc-binding residues on yeast viability. (A) Schematic diagram of Pcf11 domain organization. The zinc-binding residues are labelled as the point mutations and the relevant alleles. CID: RNAP II large subunit Carboxy-terminal domain Interacting Domain; ID: Interaction Domain. (B) Phenotypic analysis of the wild-type *PCF11* and mutant *pcf11-18* (C421S/C424S) and *pcf11-19* (C564S/C567S) strains. Ten-fold serial dilutions were plated on rich medium (YPDA) and analysed at 24, 30 and 37°C, and at 24°C on YPDA containing 2% formamide. (C) Tetrad analysis after meiosis of two independent diploid strains of YLM232 (*pcf11*Δ::HIS3/*PCF11*) transformed with the plasmid-borne *pcf11-20* allele (C421S/C424S/C564S/C567S). The four spores (A, B, C, D) coming from the same ascus (numbered horizontally) are arranged vertically. The slow growing spores corresponding to the *pcf11-20* mutants are indicated with a white arrow (spores 2B, 4C, 5C, 8B from the first diploid, and spores 5A, 8B from the second diploid).

region, and independently the conserved C564 and C567 amino acids located in the second region, were mutated into serine and the resulting mutants, named *pcf11-18* and *pcf11-19*, respectively, were assayed for growth at different temperatures (Figure 1B). Mutant *pcf11-18* did not show any strong growth defect at physiological temperatures of 24°C or 30°C. In contrast, cell growth was significantly affected at 37°C and addition of 2% formamide in the medium exacerbated this phenotype at 24°C in comparison to the wild-type strain. Unlike the *pcf11-18*, *pcf11-19* exhibited a strong growth defect at both 24°C and 30°C and turned out to be lethal at 37°C or in the presence of formamide at 24°C. We next constructed an allele that combined the mutations present in *pcf11-18* and *pcf11-19* such that both putative zinc-binding motifs were mutated. The resulting al-

lele, *pcf11-20*, was cloned into a *LEU2*-marked plasmid and used to transform the heterozygous *pcf11*Δ::HIS3/*PCF11* diploid strain YLM232 (see Materials and Methods and Table 3). After meiosis, only a few spores were observed showing a very strong slow-growth phenotype (Figure 1C; the spores are indicated with an arrow). These spores corresponded to the *pcf11*Δ::HIS3 null allele complemented with the *pcf11-20* mutant since they grew on a synthetic medium lacking histidine and leucine. This mutant therefore has a much stronger growth defect in comparison to the *pcf11-19* allele. Despite the centromeric nature of the plasmid carrying the *pcf11-20* allele, only a few spores corresponding to the mutant were able to grow (spores 2B, 4C, 5C, 8B from the first diploid, and spores 5A, 8B from the second diploid, Figure 1C). After inspection under the mi-




Figure 2. Recombinant CF IA works efficiently in mRNA 3'-end formation. (A) CF IA was reconstituted by co-expression of the four CF IA subunits in *E. coli*. Each subunit was alternatively fused at its N-terminus with a hexahistidine tag allowing for protein purification. Pull-down experiments were performed from 10 ml cell culture after immobilization on affinity-resin. The bound proteins were eluted with imidazole and analyzed by a 10% SDS-PAGE. Proteins were revealed by Coomassie-blue staining. The asterisk (*) refers to the His-tagged subunit of CF IA. (B) *In vitro* cleavage assay with the *CYC1* precursor was performed in the presence of native CPF (nCPF) and wild-type native CF IA (nCF IA^{WT}) purified by TAP-tagging (lane 8) or recombinant CF IA (rCF IA- ΔQ_{20} ; lane 9). Hrp1 was included in the reaction to avoid cleavage at cryptic sites. Lanes 1 and 7: unreacted *CYC1* precursor; lanes 1–6: negative controls showing the absence of cleavage activity of the different factors on their own. Lane 5 shows however the intrinsic and normal polyadenylation activity of Pap1-containing CPF. (C) *In vitro* polyadenylation assay of the *CYC1* precleaved precursor (*CYC1*pre) with nCF IA^{WT} (lane 5) or rCF IA- ΔQ_{20} (lane 6) and nCPF, Hrp1 and Pab1. The latter is required to control poly(A) tail elongation. Lanes 1 and 4: unreacted *CYC1*pre precursor; Lane 2: nCPF alone can polyadenylate unspecifically *CYC1*pre; lane 3: Hrp1 and Pab1 are inactive on their own.

croscope, many of the spores did not go beyond one or two cell divisions. Therefore, the *pcf11-20* mutant conferred a strong germinative defect and a near-lethal phenotype for those spores which were able to escape germination.

In conclusion, the mutations of putative Pcf11 zinc-binding cysteines designed to abolish metal chelation in both the C₂H₂ and CCHC regions led to a clear growth defect, and thus supports a general need for Zn²⁺ binding in Pcf11 function.

Recombinant expression of CF IA

Prompted by the cell growth defects in the mutations described above and in order to circumvent native CF IA purification from these alleles, we first set-up a procedure for reconstituting *S. cerevisiae* CF IA from bacterially expressed proteins as previously described (22). This approach allows for the study of CF IA containing deletions of essential domains (e.g. Pcf11 CID) or point mutations that cannot be studied *in vivo* due to their lethal phenotype, and

thus enable studies on CF IA architecture and pre-mRNA 3'-end processing. Briefly, each subunit was cloned into a plasmid carrying a resistance to a different antibiotic allowing for the introduction of up to four plasmids at a time into a single bacterial cell (30,31,45). Due to limited levels of protein expression of full-length Pcf11 (data not shown), we opted for a slightly altered version of Pcf11 in which a 20-aminoacid stretch of glutamine residues has been deleted (residues 234–253). This shorter version of Pcf11 is viable and has no detectable phenotype in yeast (Supplementary Figure S2), and will be referred to as Pcf11- Δ Q₂₀.

The expression of individual proteins was confirmed (Figure 2A). Subsequently, a four-subunit co-expression assay was attempted by swapping the His-tag alternatively to the N-terminus of each subunit. Each combination successfully retrieved the entire recombinant CF IA (rCF IA), however the best combination was found when Rna15 is Histagged (Figure 2A). A robust purification procedure was then set-up in order to retrieve pure rCF IA- Δ Q₂₀ complex for further experiments (see Materials and Methods).

rCF IA retains *in vitro* 3'-end processing activity

CF IA is essential in pre-mRNA 3'-end processing through its role in the positioning of the catalytically active CPF complex onto the pre-mRNA. We used an *in vitro* reconstituted cleavage and polyadenylation assay to test whether rCF IA is able to substitute for the yeast native complex (referred to here as nCF IA). As expected, nCF IA in combination with TAP-purified nCPF readily processed the *CYCI* precursor in a cleavage-only reaction (where polyadenylation is inhibited with EDTA and Hrp1 added to control cleavage site selection (8); Figure 2B, lane 8), as well as in a polyadenylation reaction in which Hrp1 and Pab1 were also added (Figure 2C, lane 5). Note that none of the different factors used in the assays exhibit any processing activity on their own (Figure 2B, lanes 1–4, 6 and 2C, lane 3) except for CPF which is capable of non-specific polyadenylation activity on any RNA due to the presence of the poly(A) polymerase Pap1 as one of its intrinsic subunits as previously described in the literature (e.g. (40,46)) (Figure 2B, lane 5 and 2C, lane 2). With the recombinant complex, the cleavage and polyadenylation reactions appeared as efficient when rCF IA- Δ Q₂₀ replaced native nCF IA in the assays (Figure 2B, lane 9, and 2C, lane 6, respectively). Therefore, Pcf11- Δ Q₂₀ can efficiently work in recombinant rCF IA compared to native nCF IA, as far as *in vitro* 3'-end processing is concerned.

Pcf11 contains two Zn²⁺ atoms

rCF IA provides an ideal source to quantify the Zn²⁺ content in the complex by atomic absorption, as well as recombinant sub-complexes of Rna14–Rna15 and Pcf11–Clp1 heterodimers. Samples were analysed at 213.9 nm using the dialysis buffer as the baseline, and a titration curve ranging from 1.25 to 20 μ M of ZnSO₄ solution was also prepared in the dialysis buffer. According to these measurements, only trace amounts of Zn²⁺ were detected in the Rna14–Rna15, whereas the rCF IA and Pcf11–Clp1 samples displayed significant Zn²⁺ content (Table 1). These data demonstrate the




Figure 3. Pcf11 has two zinc-binding domains. Deconvoluted ESI mass spectra obtained from (A) Pcf11 (403–626) and (B) Pcf11 (530–626) constructs under denaturing (upper panels) and non-denaturing (lower panels) conditions. Mass differences between denaturing and non-denaturing spectra respectively correspond to the binding of two (+130.5Da) and one (+65.7Da) zinc atoms.

presence of natively bound Zn²⁺ atoms within rCF IA and most specifically within Pcf11, since the structure of Clp1 did not reveal any bound Zn²⁺ atoms (18,19).

To further identify an exact stoichiometry and to better define the zinc-binding regions in Pcf11, we used mass spectrometry analysis in non-denaturing conditions. We first designed a construct from residue 403 to the C-terminus (residue 626) that spans the two-potential zinc-binding regions. The protein was expressed in *E. coli* and purified to homogeneity and the accurate Zn²⁺ stoichiometry was determined by comparing the mass measured under non-denaturing or denaturing conditions (Figure 3). The mass spectrometry data obtained under non-denaturing conditions fit the theoretical value expected for Pcf11 (403–626) of 25 742.5 Da, which includes a G–H–M tripeptide at the N-terminus. Mass spectrometry measurement under native conditions shows an additional molecular mass of 130.5 Da corresponding to two bound Zn²⁺ atoms (Figure 3A). As a final test, the second C-terminal zinc-binding region of Pcf11 (residues 530–626) was expressed in isolation. The mass under denaturing conditions of 11 149.3 \pm 0.1 Da again fits the theoretical value. Comparison to the denaturing conditions shows an additional molecular mass of

Table 1. Zn²⁺ content analysis in recombinant CF IA

Protein	[Protein] (μM)	[Zn ²⁺] (μM)	Ratio
Rna15–Rna14	3.14	0.5	0.16
CF IA-ΔQ ₂₀	6.15	11	1.79
Pcf11-ΔQ ₂₀ -Clp1	17	23.5	1.38

65.7 Da, attributed to a single bound Zn²⁺ atom (Figure 3B). Attempts to produce the other isolated zinc-binding region from residue 403–454 failed due to excessive instability. Nevertheless, the results demonstrate that Pcf11 harbors two zinc-binding regions: one Zn²⁺ binds at the C-terminus (from 530–626), and another is likely bound by the conserved amino acids within 403–454. Further insight into the architecture of these domains necessitated a structural approach.

The Pcf11 C-terminal zinc-binding domain has a novel fold

To obtain atomic information on both zinc-binding domains from Pcf11, we first attempted to determine a structure of the larger complex between Pcf11 (403–626) bound to full-length Clp1. Even though crystals diffracting to a limited resolution (<4 Å) were obtained, no electron density could be attributed to Pcf11 apart from the Clp1 interacting domain, as has been previously described (18,19). Due to the inability to produce the first zinc-binding domain in isolation, we focused on determining the structure of the second zinc-binding domain of Pcf11 (530–626). By using NMR spectroscopy, we found that the Pcf11 (530–626) construct indeed contains a well folded domain, as well as a significant number of residues that fall within the region typical of a conformationally disordered peptide (Figure 4A). It was also apparent that Zn²⁺ binding was required to maintain the overall fold, since the protein was unstable in the absence of added Zn²⁺ during purification. Although it was not possible to assign the chemical shift values of the N- and C-terminal residues, a central region from G548 to T603 was amenable to detailed structural analysis by NMR-derived dihedral and distance restraints (Figure 4B, Table 2 and Materials and Methods). To prevent bias of the Zn²⁺ binding residues during structure calculation, the protein fold was first determined without any Zn²⁺-based restraints. This calculated ensemble presented a consistent and favorable Zn²⁺ binding geometry formed by the side chains of C564, C567, H596 and C599. Therefore, a final refinement step in explicit water was performed, with the addition of a Zn²⁺ ion and a limited set of distance and dihedral restraints derived from an analysis of Zn²⁺ coordination in proteins (47). The overall structure is composed of seven β-strand elements and a single C-terminal α-helix (Figure 4C). The relatively large zinc-binding domain and high content of β-strands suggested an unusual zinc-binding fold. A recent structure of a similar region of Pcf11 from residues 538 to 608 (PDB ID 2NAX; (29)) displays the same overall fold, with a global RMSD between the two ensembles of 0.7 and 1.3 Å for the backbone and all heavy atoms, respectively, calculated by using SuperPose (48).

A search of the available structures by using DALI (49) failed to find a close structural homologue, but instead iden-




Figure 4. Solution structure of the second zinc-binding domain. (A) ¹H, ¹⁵N HSQC of [¹⁵N]-labelled Pcf11 (530–626) in 50 mM Tris (pH 7.5) and 150 mM NaCl, collected at 298 K. Crosspeaks corresponding to residues G548 to T603 have been annotated. (B) Backbone traces for the ensemble of 15 structures calculated for residues 548–603. The Zn²⁺ ion is displayed as a sphere. (C) Cartoon representation of the structure closest to the mean, with secondary structure elements labelled and the Zn²⁺ ion shown as a sphere. The zinc-binding residues are shown in stick form and are labelled. (D) Comparison of the local region of structure similarity between the second zinc-binding domain of Pcf11 (top) to only one of the two zinc-binding sites of the RING finger proteins (bottom), in this case from RFP165 (PDB 5D0I; (50)).

tified local homology (*Z*-score > 2) to one of the two zinc-binding sites within the RING finger fold (Figure 4D). For example, comparison to the recent structure from RING finger protein 165 (RFP165; PDB ID 5D0I; (50)) reveals a common β-turn placement of the first two cysteine residues in a C-x-I-C motif (C564 and C567 in Pcf11; C294 and C297 in RFP165), as well as a helical location of the remaining

Table 2. Statistics for the ensemble of 15 lowest energy structures of Pcf11 residues 548–603

NMR distance and dihedral restraints	
Distance restraints	
Total	1170
Intraresidue	353
Sequential ($ i-j = 1$)	160
Medium range ($1 < i-j < 5$)	54
Long range ($ i-j > 4$)	332
Ambiguous	271
Dihedral angle restraints	
Φ	51
Ψ	51
χ	32
Zn ²⁺ coordination restraints	
Distance	4
Dihedral	13
Structure statistics	
Violations (mean and SD)	
Distance restraints (Å)	0.010 ± 0.001
Dihedral angle restraints (°)	0.76 ± 0.09
Deviations from idealized geometry	
Bond lengths (Å)	0.001 ± 0.000
Bond angles (°)	0.300 ± 0.005
Impropers (°)	0.22 ± 0.01
Ramachandran plot (%) ^{a,b}	
Most favored regions	91.0 (95.9) ^c
Additionally favored regions	7.8 (4.1)
Generally allowed regions	0.4 (0.0)
Disallowed regions	0.8 (0.0)
Average pairwise rmsd (Å) ^a	
Backbone	0.6 (0.4)
Heavy	1.0 (0.9)

^aUsing the Protein Structure Validation Software suite (71).

^bPROCHECK (72).

^cNumber in parentheses for ordered regions: 549–555, 561–602.

H-x-x-C motif (H596 and C599 in Pcf11; H317 and C320 in RFP165). The rest of the Pcf11 fold has no structural similarity to the RING finger. As a result, it appears that the second zinc-binding region at the C-terminus of Pcf11 is a new structural class of the CCHC zinc-binding family (51). Other members of the CCHC family are mainly found in the nucleocapsid protein of retroviruses and are generally involved in packaging and early infection process. In eukaryotes, it is found in proteins binding RNA or single-stranded DNA.

A sequence alignment was then used to identify putative functional residues within the second zinc-binding domain (Figure 5A). Outside of the CCHC residues, only W582 is identical in all 13 species. This residue is found to be >40% solvent exposed in the structural ensemble by using the NACCESS program (52) and is thus able to contribute to biomolecular interactions. By extending the alignment analysis to residues that share sidechain properties in all 13 species, several residues around the zinc-binding site are identified (Figure 5B) which may contribute directly to Zn²⁺ binding properties (e.g. E569, N585, E602). Opposite to the zinc-binding residues, the aromatic amino acid (Y575) and two acidic residues (E577 and E578) cluster with W582 (Figure 5B). This conserved surface therefore presents a region of four exposed sidechains anchored in the triple-stranded β -sheet, specifically within strands β 4 and β 5 as well as the turn that connects them. This area may provide

a binding surface for interaction with CPF subunits. Comparison of this region to the surface charge properties (Figure 5C) emphasizes the acidic and exposed nature of this region.

Zinc-binding mutations have little effect on CF IA assembly

Subunit–subunit interactions in CF IA have been reported through pairwise assays either with the two-hybrid analysis or by pairwise association/expression (13,16,17,20,41,43,53) giving rise to a refined interaction map in CF IA (26). However, interactions between two proteins that require a third stabilizing protein may not be detected, as for example with the PYM protein interaction with Mago and Y14 (54). We thus used our CF IA reconstitution assay to refine the subunit-subunit interaction map with respect to Pcf11, and to test whether the zinc-binding domains are necessary for CF IA assembly. We first tested the influence of double point mutations C421S/C424S (Pcf11-18) or C564S/C567S (Pcf11-19) in a pairwise coexpression assay between Pcf11 and Clp1 (Figure 6A, left panel). As observed, no significant decrease in binding between Pcf11 (331–626) and Clp1 was detected. We next addressed the effect of these double mutations on CF IA architecture (Figure 6A, right panel). The Pcf11 Δ Q₂₀ protein carrying the double mutations C421S/C424S (Pcf11-18) or C564S/C567S (Pcf11-19) did not alter significantly the presence of any CF IA subunit in comparison to the wild-type in pull-down assays.

We also tested the impact of the double cysteine mutants on the assembly of the native nCF IA complex (nCF IA). The mutant nCF IA factors were purified by the TAP-tagging method from strains YJG23 and YJG24, where Pcf11 was expressed from the *pcf11-18* and *pcf11-19* alleles, respectively (Figure 1 and Table 3). It should be noted that purifications of nCF IA from the mutant strains reproducibly retrieved lower amounts of factors compared to the wild-type strain for unknown reasons but likely related to the relative effects of the mutations on cell growth and viability. Nevertheless, all four subunits were present in nCF IA purified from the wild-type and mutant backgrounds (Figure 6B, lanes 1–3), but the bands corresponding to Pcf11 appeared slightly less abundant in the zinc-binding domain mutant alleles. Based on this silver-stained protein gels, equal amounts of factors were loaded on SDS-polyacrylamide gels and subjected to Western blot analyses with antibodies to all four subunits separately. The blots showed that, in comparison to equivalent signals detected with anti-Rna14 and anti-Rna15, the association of Pcf11 and also Clp1 was slightly impaired in the mutant factors (Figure 6C). With regard to nCF IA purified from the most affected mutant, the *pcf11-19* allele, the Pcf11 mutant protein appeared to be more prone to degradation and was revealed as double bands yet both capable to associate with nCF IA (Figure 6B, lane 3 and Figure 6C, lane 3, panel α -Pcf11). Nevertheless, the consequence of cysteine mutations in the zinc-binding motifs on nCF IA assembly is not dramatic enough to explain their impact on *pcf11-18* and particularly *pcf11-19* growth phenotypes.




Figure 5. Surface residue conservation separate from the zinc-binding site. **(A)** Sequence alignment of the second zinc-binding domain of Pcf11 from 13 species. Boundaries of the construct used in NMR studies (residues 530–626) and of the calculated structure (residues 548–603) are indicated, as are the locations of β -strands (arrows) and the α -helix (cylinder). Solvent accessibility for sidechains are calculated by using NACCESS (52) and indicated with varying shades of blue squares from solid blue (>80% accessible) to white (<20% accessible). Residues with complete sequence identity or similarity is highlighted in black and orange, respectively. Residues with similarity to yeast Pcf11 in >75% of the sequences are highlighted in light orange. **(B)** Surface representation of Pcf11 (548–603) with residues coloured by conservation as in panel A. The conserved patch formed by residues Y575, E577, E578 and W582 as well as the conserved residues around the Zn^{2+} atom (E569, V583, N586, E602) are indicated. **(C)** Surface charge properties of Pcf11 (548–603) with the negatively charged acidic regions in red, and the positively charged basic regions in blue.

Table 3. Yeast strains used in this study

Strain	Genotype
YLM232	<i>MATα, pcf11Δ::HIS3/PCF11, ade2-1/ade2-1 leu2-3,112/leu2-3,112 ura3-1/ura3-1 trp1-1/trp1Δ his3-11,15/his3-11,15 can1-100 GAL+</i>
YLM233	<i>MATα, pcf11Δ::HIS3, pFL38-PCF11, ade2-1 leu2-3,112 ura3-1 trp1 his3-11,15 can1-100 GAL+</i>
YLM237	<i>MATα, pcf11Δ::HIS3, pFL36ΔSX-PCF11, ade2-1 leu2-3,112 ura3-1 trp1Δ his3-11,15 can1-100 GAL+</i>
YLM221	<i>MATα, [pNOP1]-TAP::RNA15-TRP1-Kl, ade2-1 leu2-3,112 ura3-1 trp1 his3-11,15 can1-100 GAL+</i>
YLM244	<i>MATα, pcf11Δ::HIS3, pFL36ΔSX-PCF11, [pNOP1]-TAP::RNA15-TRP1-Kl, ade2-1 leu2-3,112 ura3-1 trp1Δ his3-11,15 can1-100 GAL+</i>
YJG10	<i>MATα, pcf11Δ::HIS3, pFL36ΔSX-pcf11-18 (C421S,C424S), ade2-1 leu2-3,112 ura3-1 trp1Δ his3-11,15 can1-100 GAL+</i>
YJG23	<i>pcf11Δ::HIS3, pFL36ΔSX-pcf11-18 (C421S,C424S), [pNOP1]-TAP::RNA15-TRP1-Kl ade2-1 leu2-3,112 ura3-1 trp1Δ his3-11,15 can1-100 GAL+</i>
YJG12	<i>MATα, pcf11Δ::HIS3, pFL36-pcf11-19 (C564S,C567S), ade2-1 leu2-3,112 ura3-1 trp1Δ his3-11,15 can1-100 GAL+</i>
YJG24	<i>pcf11Δ::HIS3, pFL36-pcf11-19 (C564S,C567S), [pNOP1]-TAP::RNA15-TRP1-Kl, ade2-1 leu2-3,112 ura3-1 trp1Δ his3-11,15 can1-100 GAL+</i>
YLM239	<i>MATα, pcf11Δ::HIS3, pFL36ΔSX-pcf11ΔQ₂₀, ade2-1 leu2-3,112 ura3-1 trp1Δ his3-11,15 can1-100 GAL+</i>
YJG35	<i>rna15-1, [pNOP1]-TAP::FIP1-TRP1-Kl, ade2-1 leu2-3,112 ura3-1 trp1Δ his3-11,15 can1-100 GAL+</i>

Mutations of the zinc-binding motifs impair mRNA 3'-end formation to different extents

We next examined the involvement of Pcf11 zinc-binding domains in mRNA 3'-end maturation *in vitro*. We assayed nCF IA factors purified from the wild-type and the mutant *pcf11-18* and *pcf11-19* strains in either cleavage or polyadenylation reactions at 30°C. As controls, no cleavage or polyadenylation activity was found with the purified factors on their own (Supplementary Figure S3). We took into account the lower amounts of nCF IA complexes retrieved from the mutant strains after TAP purification compared to wild-type as judged by the differences observed on protein gels (see Figure 6B and C) to carry out the assays.

Moreover, to circumvent the variabilities observed in the Pcf11–Clp1 protein contents and their possible impact on 3' processing activities, we performed the cleavage assays with increasing amounts of the different nCF IA factors. Efficient and very similar endonucleolytic cleavage of the *CYC1* full-length precursor was obtained when nCF IA^{WT} (Figure 7A, lanes 3–5) or nCF IA^{pcf11-18} (Figure 7A, lanes 6–8) was used in the assay. Conversely, cleavage activity was undetectable with nCF IA^{pcf11-19} no matter the amount of factor employed (Figure 7A, lanes 9–11). The possibility that the recombinant wild-type domain of Pcf11 could ameliorate the cleavage activity of mutant and wild-type nCF IA was tested. Starting from the same reaction conditions used in




Figure 6. The Pcf11 zinc-binding domains do not participate in CF IA assembly. (A) Pull-down assays of recombinant Pcf11-Clp1 and CF IA. The C421S/C424S point mutations and C564S/C567S point mutations were introduced into the ORF of Pcf11 (311–626) or Pcf11 ΔQ20. Pcf11:Clp1 or CF IA was pulled-down via a His-tag at the N-terminus of Pcf11. Proteins were eluted from the beads with imidazole and analysed by SDS-PAGE followed by Coomassie-Blue staining. Equivalent amounts of native wild-type and mutant TAP-purified CF IA were loaded on SDS–12% polyacrylamide gels and subjected to silver staining (B) or Western blot (C) analyses. Lanes 1: 5 μl of purified nCF IA^{WT}; lanes 2: 20 μl of nCF IA^{Pcf11-18}, lanes 3: 20 μl of nCF IA^{Pcf11-19} were used. Polyclonal antibodies to each individual CF IA subunits were used to probe the Western blots.

lanes 4, 7 and 10 of Figure 7A, we complemented the assays with 100 ng of either recombinant Pcf11^[403-626]-Clp1 or Pcf11^[403-626] alone. No significant improvement was observed with nCF IA^{WT} or nCF IA^{Pcf11-18} with Pcf11^[403-626]-Clp1 dimer but a slight inhibition could be noticed after addition of Pcf11^[403-626] alone (Figure 7B, lanes 2–4 and 5–7). Cleavage assays with nCF IA^{Pcf11-19} was not dramatically changed with either proteins (Figure 7B, lanes 8–10). Therefore, reconstitution of an active factor or stimulation of the activity was not possible by simply complementing the assay with wild-type domains alone.

We then performed polyadenylation assays with the same wild-type and mutant factors. In these conditions, less efficient polyadenylation of the *CYCI* pre-cleaved precursor was reproducibly obtained with nCF IA^{Pcf11-18} compared to the wild-type factor (Figure 7C, lanes 4 and 3). In contrast, the absence of characteristic polyadenylated product was observed with the nCF IA^{Pcf11-19} mutant factor (Figure 7C, lane 5). Therefore, the impact on pre-mRNA 3'-end processing *in vitro* may likely explain the growth defects seen

when Pcf11 zinc-binding motifs are mutated. Noticeably, these deficiencies also parallel the amplitude of the growth defects observed with the two mutants (Figure 1B).

RNA polymerase II transcription termination in Pcf11 zinc-binding mutants

The C-terminal position of the two Pcf11 zinc-binding motifs would predict that they are not important for RNA polymerase II (RNAPII) transcription termination as it has been demonstrated that only mutations in the 266 N-terminal aminoacids of the protein affect termination (43). To test this assumption, an S1 nuclease protection assay was developed to map the 3' ends of an RNAPII-transcribed gene coding for a stable snoRNA, *snR13* (see Materials and Methods). Briefly, we designed a probe capable to hybridize with RNAs transcribed from the *snr13-TRS31* region of the genome (Figure 8A). This ³²P-5'-end-labeled probe (Figure 8B, lane 1) is sensitive to extensive degradation when subjected to S1 nuclease treatment when alone or in the pres-




Figure 7. Mutations in the zinc-binding motifs have distinct effects on 3'-end processing. **(A)** Pre-mRNA cleavage assay on the *CYC1* precursor with TAP-purified factors from wild-type (nCF IA^{WT}) and mutant (nCF IA^{pcf11-18} and nCF IA^{pcf11-19}) cells. Lane 1: unreacted *CYC1* precursor, lane 2: nCPF and Hrp1 were assayed as negative controls for the lack of cleavage activity in the absence of CF IA. Increasing amounts of nCF IA^{WT} (0.5 μ l, 1 μ l and 2 μ l; lanes 3–5) or nCF IA^{pcf11-18} or nCF IA^{pcf11-19} (2 μ l, 4 μ l and 8 μ l lanes 6–8 and 9–11, respectively) were added to nCPF and Hrp1 to carry out the cleavage reaction. **(B)** Complementation of cleavage assays. Cleavage reactions were run as in (A) with 1 μ l of nCF IA^{WT} or 4 μ l of nCF IA^{pcf11-18} or nCF IA^{pcf11-19}. 100 ng of recombinant Pcf11⁽⁴⁰³⁻⁶²⁶⁾-Clp1 (lanes 3, 6, 9) or Pcf11⁽⁴⁰³⁻⁶²⁶⁾ (lanes 4, 7, 10) were added to the reaction as indicated. Lane 1: unreacted *CYC1* precursor. Lane 2: nCPF+Hrp1 were incubated with *CYC1* as a negative control. **(C)** Polyadenylation assays performed on the *CYC1* pre-cleaved precursor (*CYC1pre*) with the same amounts of nCF IA^{WT}, nCF IA^{pcf11-18} and nCF IA^{pcf11-19} as in (B). Pab1 (140 ng) was added to the reaction to control *de novo* synthesis of poly(A) tails.




Figure 8. The zinc-binding domains do not participate in RNA polymerase II transcription termination at snoRNA genes. (A) Schematic representation of the S1 nuclease protection assay to map transcription termination at *snR13* transcription unit. (B) Detection of *snR13* read-through products by S1 nuclease protection. The radiolabeled probe (P, lane 1) was incubated with S1 nuclease either alone (lane 2) or in the presence of non-specific RNAs (tRNA; lane 3), a specific RNA designed to protect a 142-nt fragment (lane 4), or total RNAs extracted from wild-type or mutant cells grown at 24°C or after a shift to 37°C during 60 min (lanes 5–12). The protected fragments were separated by electrophoresis on 8% polyacrylamide–8.3 M urea gels. The bands on the gels were indicated as diagrammed in (C). The labeled molecular weight makers (in number of nucleotides) are the *Msp* I-digested pBR322 (M₁) and the 100-bp DNA ladder (Promega; M₂).

ence of unspecific tRNA (Figure 8B, lanes 2–3). As a positive control, hybridization of the probe with a specific synthetic RNA of about 190 nucleotides transcribed from a region comprising part of the *snR13* mature transcript downstream sequences, generated a predicted fragment of 142 nucleotides (Figure 8B, lane 4). Total RNAs extracted from the wild-type *PCF11* strain cultivated at both 24°C or after a 1-hour shift to 37°C only produced a 78-nt product (M) in the assay representing the mature form of *snR13* snoRNA (Figure 8B, lane 5–6). RNAs isolated from a temperature-sensitive allele, *pcf11-24*, containing mutations in the N-terminal domain of the Pcf11 protein (J. Guéguéniat *et al.* personal communication), produced the 78-nt product at both temperatures but also a 450-nt fragment (RT) at 37°C corresponding to read-through transcription downstream of the normal transcription termination site of *snr13* (Figure 8B, lane 7–8). Mutations of the two Pcf11 zinc-binding motifs produced no detectable read-through transcript in the S1 nuclease protection assay but only the mature one (M), as anticipated from the localization of the domains affected by the mutations (Figure 8B, lanes 9–12). In conclusion, our data suggest that in contrast to the noticeable effect on mRNA 3' end formation, the zinc-binding domains have likely no role in RNAPII transcription termination of snoRNA *in vivo*.

Pcf11 zinc-finger domains can bind RNA in the absence of Clp1 with different avidities

The presence of zinc-binding motifs in polypeptides is

sometimes associated with an ability to bind nucleic acids. This is often the case with proteins involved in RNA processing. Even though the structure of the Pcf11 C-terminal zinc-binding domain has no overall structural homology with classical zinc fingers, we tested whether the region of Pcf11 containing the two zinc-binding motifs can associate with RNA. After confirming that equal amounts of the Pcf11 zinc-binding domains were used with a Coomassie-stained gel (Figure 9A), we performed UV cross-linking experiments with uniformly ³²P-labeled *CYCI* substrate, using recombinant Rna15 as a positive control and testing recombinant Pcf11^[403–626]-Clp1 (Figure 9B, lanes 1 and 2). As expected, a strong signal corresponding to Rna15 binding to the RNA was observed after SDS-PAGE and autoradiography of the gel (Figure 9B, lane 1). This interaction is due to the presence of a canonical RNP-type RNA-binding domain at the Rna15 N-terminus. Conversely, no signal was obtained in the same assay conditions with Pcf11^[403–626]-Clp1 heterodimer (Figure 9B, lane 2). It has been previously shown that the region of Pcf11 encompassing the Clp1 binding site flanked by the two zinc finger domains binds not only Clp1 but also the RNA-binding protein and export factor Yra1 in a mutually exclusive mode (55). In competition experiments, the interaction between Yra1 and Pcf11 zinc-binding regions was lost after addition of Clp1 or RNA, despite the fact that the Yra1 RRM is not involved in the interaction between the proteins (56). To test whether the association of Pcf11^[403–626] with Clp1 could mask an intrinsic capacity of the zinc finger domains to




Figure 9. The zinc-binding region can bind RNA in the absence of Clp1. (A) Equal amounts (600 ng) of recombinant proteins were loaded on a 12% SDS-polyacrylamide gel and stained with Coomassie. Lane 1: full-length Rna15; lane 2: Pcf11^[403-626]-Clp1; lane 3: Pcf11^[403-626]; lane 4: Pcf11-18^[403-626] mutant (C⁴²¹S/C⁴²⁴S); lane 5: Pcf11-19^[403-626] mutant (C⁵⁶⁴S/C⁵⁶⁷S). (B) Equal amounts (100 ng) of recombinant proteins as described in (A) were incubated in the presence of ³²P-labeled *CYC1* transcript and subjected to UV cross-linking, in the absence (left panel) or presence of an excess of competitor yeast total RNA (5 µg; right panel). The position of the different polypeptides is indicated.

interact with RNA, we extended the UV cross-linking experiments to the Pcf11^[403-626] region of the wild-type protein alone and of the corresponding mutant polypeptides Pcf11-18^[403-626] and Pcf11-19^[403-626] (Figure 9A, lanes 3–5). As hypothesized before, the absence of Clp1 revealed that the zinc-binding region of Pcf11 was able to effectively interact with *CYC1* (Figure 9B, lane 3). Strikingly, the mutant Pcf11-18^[403-626] polypeptide exhibited a strong signal comparable to that of Rna15 in the same assay conditions (Figure 9B, compare lane 4 and 1). Pcf11-19^[403-626] was also prone to cross-link to the labeled RNA but in a manner similar to the wild-type protein (Figure 9B, lane 5 and 3). To evaluate the strength and/or specificity of Pcf11^[403-626]-RNA interaction, we challenged *CYC1* binding by incubating the proteins with an excess (5 µg) of total yeast RNA before adding the labeled transcript (see Materials and Methods). The right panel of Figure 9B showed that albeit diminished, Rna15 still exhibited a significant interaction with RNA (lane 6) but *CYC1* interaction was lost for all of the Pcf11^[403-626] versions (lanes 7–10). These experiments showed that Pcf11 zinc-binding domains have the capacity to bind non-specifically to RNA but only in the absence of another protein or RNA interactor.

DISCUSSION

In this article, we report the biochemical, biophysical and biological characterization of the two zinc-binding domains of Pcf11. The identified zinc-binding domains surround the Clp1 binding region (residues 454–530) and are located between residues 403–454 and 530–626, belonging to the C₂H₂ and CCHC class respectively (57). The zinc-binding domain spanning aminoacids 403–454 was the first to be identified (44) while both domains were more carefully depicted from the sequence of Pcf11 (43). Of note, the struc-

tural and functional analysis of the second zinc-binding domain was recently published (29). Mass spectrometry measurements demonstrate that each domain binds a single Zn²⁺ atom, and each zinc-binding domain displays a thermo-sensitive phenotype when two out of the four Zn²⁺ binding residues are mutated into serine. Simultaneous mutation of the two zinc-binding domains is close to lethality in yeast. We further demonstrate that these Pcf11 domains are not required for transcription termination in yeast and are involved to different degrees in pre-mRNA 3'-end processing *in vitro*.

CF IA bearing an altered version of Pcf11 in its first zinc-binding domain can efficiently cleave a pre-mRNA substrate and has only slightly impaired polyadenylation activity as compared with the wild-type factor. In contrast, the equivalent mutations in the second zinc-binding motif have a dramatic effect on both cell growth and 3' processing. The overall assembly of the factor is mostly unchanged from the wildtype which is different than mutations in the Clp1 protein that abolished the association of Clp1 and Pcf11 with Rna14–Rna15 (53), or mutations in Rna14 or Rna15 which were described to impair CF IA subunit organization (16).

Along with this study, we also demonstrate that the poorly-conserved poly-glutamine extension of Pcf11 (residues 234–253), connecting the N-terminal CID to the Rna14–Rna15 binding domain, is not necessary for CF IA assembly. The poly-glutamine linker is also not required for mRNA 3' end maturation, which likely explains the viability of *pcf11* Δ_{Q20} mutant. As suggested by Amrani and colleagues (9), the poly-glutamine extension could confer a degree of freedom to the N-terminal and C-terminal domains, allowing them to fulfil independent functions. This possibility is reinforced by the observation that the region between residues 253 and 331 of Pcf11 is not otherwise necessary to assemble CF IA and may mainly function to extend the

linker region by more than 75 residues. This type of organization is also observed for Nab2, implicated in the regulation of the poly(A) tail length (58,59). Nab2 also exhibits a repetition of 12 glutamine residues linking the N-terminal domain related to mRNA export function, and the RNA interacting region located at the central and C-terminal regions. Interestingly, deletion of the Q-rich region of Nab2 also has no impact on pre-mRNA 3'-end processing either (10).

We have also reported the solution structure of the second zinc-binding domain of Pcf11. Similar to the findings by the Varani and Moore labs (29) the overall fold does not exhibit similarity to other reported zinc-binding domains. So far only CCCH-type zinc knuckles have been characterized among the proteins involved in mRNA 3'-end maturation. This includes Mpe1, an essential protein required for both cleavage and polyadenylation, that contains a central zinc knuckle (60), Nab2 (58,59,61) and Yth1 that contains five zinc knuckle domains (62,63). It should be noted, however, that mutant analysis for zinc-binding residues in these domains, as performed for Pcf11, have not been described. Previously reported *PCF11* alleles, such as *pcf11-2* (E232G, D280G, C424R, S538G, F562S, S579P) or *pcf11-9* (A66D, S190P, R198P, R227G, E354V, K435V) exhibit only a thermo-sensitive phenotype (9,43). Cysteine mutations within Mpe1 or Nab2 lead to a cold sensitive phenotype and no detectable effect on growth at 37°C (58,60). The phenotype difference reported in this article may also illustrate the functional independence of each zinc-binding domain. Indeed, for the five CCCH domains of Yth1 there is variation in function: ZF2 and ZF4 interact with RNA, ZF4 and ZF5 interact with Fip1, ZF1 and ZF4 interact with the endonuclease Ysh1/Brr5 and ZF1 and ZF2 are required for pre-mRNA cleavage (63).

Finally, Pcf11 is a key player in connecting RNAPII transcription termination, via its N-terminal CID, to pre-mRNA 3'-end cleavage, through its association to Clp1 and Rna14:Rna15 heterodimer. In this scheme, the Pcf11 zinc-binding domains appear to ensure the connection to pre-mRNA 3'-end processing of CF IA to CPF subunits. These zinc-binding domains may well play a regulatory role on CPF subunits. Indeed, the sole CPF is not able to cleave pre-mRNA in the absence of CF IA and Hrp1. In addition to the contacts within CF IA subunits, Pcf11 exhibits direct contacts to CPF subunits and other proteins. This is the case for Ysh1, Ydh1 and Yhh1 (64), Mpe1 (65), Ssu72 (66), Pti1 (67,68), Swd2 (69). Considering these interactions, the zinc-finger domains of Pcf11 could be seen as protein-protein interactors with specific CPF subunits. As Swd2 is not required for the cleavage and polyadenylation steps *in vitro* (69,70), yet can affect 3'-end formation of some mRNAs and snoRNAs *in vivo*, it is unlikely that a disruption of its interaction with Pcf11 could be responsible for the observed phenotypes.

Alternatively, but not in opposition, a putative role in RNA binding of the zinc-finger domain of Pcf11 has been suggested in our study. We showed that the region containing these motifs flanking the Clp1 interaction domain of Pcf11 can interact with RNA only in the absence of Clp1. This situation is reminiscent of Yra1 binding to the same region of Pcf11 as reported by David L. Bentley and

coworkers (56). Tethering of Pcf11 to the pre-mRNA enhances binding of Yra1 to the C-terminal ZF1-Clp1-ID-ZF2 region of Pcf11 before transcription termination happens. Sub2 replaces Pcf11 and interacts with Yra1 which will cause the mRNA to be competent for export. In place of Yra1, Clp1 interacts with Pcf11 within the CF IA complex at the time of transcription termination (56). We propose that during these different exchange of interactions, a transient but efficient contact of Pcf11 with the elongating pre-mRNA occurs through the C-terminal ZF1-Clp1-ID-ZF2 domain and before Clp1 recruitment to maintain Pcf11 and associated proteins such as Rna14 and Rna15 on the pre-mRNA. It is also possible that Yra1 could act as a chaperone - as also proposed by Bentley and coworkers (56) - to induce a conformational change thus unmasking the Clp1-binding site of Pcf11.

As a result, the role of the C-terminal zinc-finger domain in pre-mRNA 3'-end processing is very likely direct and mediated through protein-protein contacts made with CPF subunits that are still to be uncovered. The RNA-binding capacity of the zinc-finger mutants is probably not responsible for the observed phenotypes on growth as the purified mutant factors both showed that assembly of the complexes is maintained. We cannot however rule out that a proportion of the mutant Pcf11-19 protein is not associated to the CF IA complex *in vivo* and thus may perturb RNA processing and export, leading to the strong growth phenotype associated with the *pcf11-19* mutant.

In summary, we provide evidence that Pcf11 has two zinc-binding domains mandatory for Pcf11 function *in vivo*. Even though the exact role of each zinc-binding domain remains to be elucidated, both impact mRNA 3'-end formation to very different intensities when mutated. In comparison, transcription termination at snoRNA genes happens normally, and CF IA assembly is not affected. We propose a direct role in the interaction with specific CPF subunits or a possible function through RNA recognition during the process of coordinating 3'-end processing and mRNP export.

ACCESSION NUMBER

The structure ensemble has been deposited in the Protein Data Bank (<http://www.ebi.ac.uk/pdbe>) with PDB ID 5M9Z.

SUPPLEMENTARY DATA

Supplementary Data are available at NAR Online.

ACKNOWLEDGEMENTS

We thank Dr Yves Méchulam (Ecole Polytechnique, Palaiseau) for atomic absorption measurements. Access to NMR spectrometers, equipment and technical assistance were possible thanks to Axelle Grélard, Estelle Morvan and the structural biology platform at the Institut Européen de Chimie et Biologie (UMS 3033).

FUNDING

French National Research Agency [ANR-12-BSV8-0016 to S.F., C.D.M., L.M.-S.]; Aquitaine regional government (to

A.D. and S.F.); INSERM and the University of Bordeaux; Ministère de la Recherche Scientifique (to J.G.); Centre National de la Recherche Scientifique; Université de Strasbourg; Région Alsace (to J.S., S.C.); Centre National de la Recherche Scientifique [IR-RMN-THC Fr3050]. Funding for open access charge: INSERM, CNRS.

Conflict of interest statement. None declared.

REFERENCE

- Marzluff, W.F. (2005) Metazoan replication-dependent histone mRNAs: a distinct set of RNA polymerase II transcripts. *Curr. Opin. Cell Biol.*, **17**, 274–280.
- Mandel, C.R., Bai, Y. and Tong, L. (2008) Protein factors in pre-mRNA 3'-end processing. *Cell Mol. Life Sci.*, **65**, 1099–1122.
- Millevoi, S. and Vagner, S. (2010) Molecular mechanisms of eukaryotic pre-mRNA 3' end processing regulation. *Nucleic Acids Res.*, **38**, 2757–2774.
- Shi, Y. and Manley, J.L. (2015) The end of the message: multiple protein-RNA interactions define the mRNA polyadenylation site. *Genes Dev.*, **29**, 889–897.
- Luo, W., Johnson, A.W. and Bentley, D.L. (2006) The role of Rat1 in coupling mRNA 3'-end processing to transcription termination: implications for a unified allosteric-torpedo model. *Genes Dev.*, **20**, 954–965.
- Kessler, M.M., Henry, M.F., Shen, E., Zhao, J., Gross, S., Silver, P.A. and Moore, C.L. (1997) Hrp1, a sequence-specific RNA-binding protein that shuttles between the nucleus and the cytoplasm, is required for mRNA 3'-end formation in yeast. *Genes Dev.*, **11**, 2545–2556.
- Minvielle-Sebastia, L., Preker, P.J., Wiederkehr, T., Strahm, Y. and Keller, W. (1997) The major yeast poly(A)-binding protein is associated with cleavage factor IA and functions in pre-messenger RNA 3'-end formation. *Proc. Natl. Acad. Sci. U.S.A.*, **94**, 7897–7902.
- Minvielle-Sebastia, L., Beyer, K., Krecic, A.M., Hector, R.E., Swanson, M.S. and Keller, W. (1998) Control of cleavage site selection during mRNA 3' end formation by a yeast hnRNP. *EMBO J.*, **17**, 7454–7468.
- Amrani, N., Minet, M., Le Gouar, M., Lacroute, F. and Wyers, F. (1997) Yeast Pab1 interacts with Rna15 and participates in the control of the poly(A) tail length in vitro. *Mol. Cell. Biol.*, **17**, 3694–3701.
- Viphakone, N., Voisinnet-Hakil, F. and Minvielle-Sebastia, L. (2008) Molecular dissection of mRNA poly(A) tail length control in yeast. *Nucleic Acids Res.*, **36**, 2418–2433.
- Dunn, E.F., Hammell, C.M., Hodge, C.A. and Cole, C.N. (2005) Yeast poly(A)-binding protein, Pab1, and PAN, a poly(A) nuclease complex recruited by Pab1, connect mRNA biogenesis to export. *Genes Dev.*, **19**, 90–103.
- Bai, Y., Auperin, T.C., Chou, C.Y., Chang, G.G., Manley, J.L. and Tong, L. (2007) Crystal structure of murine CstF-77: dimeric association and implications for polyadenylation of mRNA precursors. *Mol. Cell.*, **25**, 863–875.
- Légrand, P., Pinaud, N., Minvielle-Sebastia, L. and Fribourg, S. (2007) The structure of the CstF-77 homodimer provides insights into CstF assembly. *Nucleic Acids Res.*, **35**, 4515–4522.
- Noble, C.G., Walker, P.A., Calder, L.J. and Taylor, I.A. (2004) Rna14–Rna15 assembly mediates the RNA-binding capability of *Saccharomyces cerevisiae* cleavage factor IA. *Nucleic Acids Res.*, **32**, 3364–3375.
- Paulson, A.R. and Tong, L. (2012) Crystal structure of the Rna14–Rna15 complex. *RNA*, **18**, 1154–1162.
- Moreno-Morcillo, M., Minvielle-Sebastia, L., Fribourg, S. and Mackereth, C.D. (2011) Locked tether formation by cooperative folding of Rna14p monkeytail and Rna15p hinge domains in the yeast CF IA complex. *Structure*, **19**, 534–545.
- Qu, X., Perez-Canadillas, J.M., Agrawal, S., De Baecke, J., Cheng, H., Varani, G. and Moore, C. (2007) The C-terminal domains of vertebrate CstF-64 and its yeast orthologue Rna15 form a new structure critical for mRNA 3'-end processing. *J. Biol. Chem.*, **282**, 2101–2115.
- Noble, C.G., Beuth, B. and Taylor, I.A. (2007) Structure of a nucleotide-bound Clp1-Pcf11 polyadenylation factor. *Nucleic Acids Res.*, **35**, 87–99.
- Dupin, A.F. and Fribourg, S. (2014) Structural basis for ATP loss by Clp1 in a G135R mutant protein. *Biochimie*, **101**, 203–207.
- Gross, S. and Moore, C. (2001) Five subunits are required for reconstitution of the cleavage and polyadenylation activities of *Saccharomyces cerevisiae* cleavage factor I. *Proc. Natl. Acad. Sci. U.S.A.*, **98**, 6080–6085.
- Gordon, J.M., Shikov, S., Kuehner, J.N., Liriano, M., Lee, E., Stafford, W., Poulsen, M.B., Harrison, C., Moore, C. and Bohm, A. (2011) Reconstitution of CF IA from overexpressed subunits reveals stoichiometry and provides insights into molecular topology. *Biochemistry*, **50**, 10203–10214.
- Stojko, J., Dupin, D., Chaignepain, S., Beaurepaire, L., Vallet-Courbin, A., Van Dorsseleer, A., Schmitter, J.M., Minvielle-Sebastia, L., Fribourg, S. and Cianferani, S. (2016) Structural characterization of the yeast CF IA complex through a combination of mass spectrometry approaches. *Int. J. Mass Spectrom.* doi:10.1016/j.ijms.2016.08.005.
- Perez-Canadillas, J.M. and Varani, G. (2003) Recognition of GU-rich polyadenylation regulatory elements by human CstF-64 protein. *EMBO J.*, **22**, 2821–2830.
- Leeper, T.C., Qu, X., Lu, C., Moore, C. and Varani, G. (2010) Novel protein-protein contacts facilitate mRNA 3'-processing signal recognition by Rna15 and Hrp1. *J. Mol. Biol.*, **401**, 334–349.
- Perez-Canadillas, J.M. (2006) Grabbing the message: structural basis of mRNA 3'UTR recognition by Hrp1. *EMBO J.*, **25**, 3167–3178.
- Barnwal, R.P., Lee, S.D., Moore, C. and Varani, G. (2012) Structural and biochemical analysis of the assembly and function of the yeast pre-mRNA 3' end processing complex CF I. *Proc. Natl. Acad. Sci. U.S.A.*, **109**, 21342–21347.
- Meinhart, A. and Cramer, P. (2004) Recognition of RNA polymerase II carboxy-terminal domain by 3'-RNA-processing factors. *Nature*, **430**, 223–226.
- Noble, C.G., Hollingworth, D., Martin, S.R., Ennis-Adeniran, V., Smerdon, S.J., Kelly, G., Taylor, I.A. and Ramos, A. (2005) Key features of the interaction between Pcf11 CID and RNA polymerase II CTD. *Nat. Struct. Mol. Biol.*, **12**, 144–151.
- Yang, F., Hsu, P., Lee, S.D., Yang, W., Hoskinson, D., Xu, W., Moore, C. and Varani, G. (2017) The C terminus of Pcf11 forms a novel zinc-finger structure that plays an essential role in mRNA 3'-end processing. *RNA*, **23**, 98–107.
- Fribourg, S., Romier, C., Werten, S., Gangloff, Y.G., Poterszman, A. and Moras, D. (2001) Dissecting the interaction network of multiprotein complexes by pairwise coexpression of subunits in *E. coli*. *J. Mol. Biol.*, **306**, 363–373.
- Diebold, M.L., Fribourg, S., Koch, M., Metzger, T. and Romier, C. (2011) Deciphering correct strategies for multiprotein complex assembly by co-expression: application to complexes as large as the histone octamer. *J. Struct. Biol.*, **175**, 178–188.
- Delaglio, F., Grzesiek, S., Vuister, G.W., Zhu, G., Pfeifer, J. and Bax, A. (1995) NMRPipe: a multidimensional spectral processing system based on UNIX pipes. *J. Biomol. NMR*, **6**, 277–293.
- Senn, H., Werner, B., Messerle, B.A., Weber, C., Traber, R. and Wüthrich, K. (1989) Stereospecific assignment of the methyl 1H NMR lines of valine and leucine in polypeptides by nonrandom 13C labelling. *FEBS Lett.*, **249**, 113–118.
- Shen, Y. and Bax, A. (2013) Protein backbone and sidechain torsion angles predicted from NMR chemical shifts using artificial neural networks. *J. Biomol. NMR*, **56**, 227–241.
- Hansen, D.F., Neudecker, P. and Kay, L.E. (2010) Determination of isoleucine side-chain conformations in ground and excited states of proteins from chemical shifts. *J. Am. Chem. Soc.*, **132**, 7589–7591.
- Hansen, D.F. and Kay, L.E. (2011) Determining valine side-chain rotamer conformations in proteins from methyl 13C chemical shifts: application to the 360 kDa half-proteasome. *J. Am. Chem. Soc.*, **133**, 8272–8281.
- Brunger, A.T. (2007) Version 1.2 of the crystallography and NMR system. *Nat. Protoc.*, **2**, 2728–2733.
- Linge, J.P., Habeck, M., Rieping, W. and Nilges, M. (2003) ARIA: automated NOE assignment and NMR structure calculation. *Bioinformatics*, **19**, 315–316.
- Minvielle-Sebastia, L., Preker, P.J. and Keller, W. (1994) RNA14 and RNA15 proteins as components of a yeast pre-mRNA 3'-end processing factor. *Science*, **266**, 1702–1705.

40. Dheur,S., Vo le,T.A., Voisinnet-Hakil,F., Minet,M., Schmitter,J.M., Lacroute,F., Wyers,F. and Minvielle-Sebastia,L. (2003) Pti1p and Ref2p found in association with the mRNA 3' end formation complex direct snoRNA maturation. *EMBO J.*, **22**, 2831–2840.
41. Amrani,N., Minet,M., Wyers,F., Dufour,M.E., Aggerbeck,L.P. and Lacroute,F. (1997) PCF11 encodes a third protein component of yeast cleavage and polyadenylation factor I. *Mol. Cell. Biol.*, **17**, 1102–1109.
42. Sittman,D.B., Graves,R.A. and Marzluff,W.F. (1983) Structure of a cluster of mouse histone genes. *Nucleic Acids Res.*, **11**, 6679–6697.
43. Sadowski,M., Dichtl,B., Hubner,W. and Keller,W. (2003) Independent functions of yeast Pcf11p in pre-mRNA 3' end processing and in transcription termination. *EMBO J.*, **22**, 2167–2177.
44. Barilla,D., Lee,B.A. and Proudfoot,N.J. (2001) Cleavage/polyadenylation factor IA associates with the carboxyl-terminal domain of RNA polymerase II in *Saccharomyces cerevisiae*. *Proc. Natl. Acad. Sci. U.S.A.*, **98**, 445–450.
45. Romier,C., Ben Jelloul,M., Albeck,S., Buchwald,G., Busso,D., Celie,P.H., Christodoulou,E., De Marco,V., van Gerwen,S., Knipscheer,P. *et al.* (2006) Co-expression of protein complexes in prokaryotic and eukaryotic hosts: experimental procedures, database tracking and case studies. *Acta Crystallogr. D Biol. Crystallogr.*, **62**, 1232–1242.
46. Preker,P.J., Ohnacker,M., Minvielle-Sebastia,L. and Keller,W. (1997) A multisubunit 3' end processing factor from yeast containing poly(A) polymerase and homologues of the subunits of mammalian cleavage and polyadenylation specificity factor. *EMBO J.*, **16**, 4727–4737.
47. Wang,C., Vernon,R., Lange,O., Tyka,M. and Baker,D. (2010) Prediction of structures of zinc-binding proteins through explicit modeling of metal coordination geometry. *Prot. Sci.*, **19**, 494–506.
48. Maiti,R., Van Domselaar,G.H., Zhang,H. and Wishart,D.S. (2004) SuperPose: a simple server for sophisticated structural superposition. *Nucleic Acids Res.*, **32**, W590–594.
49. Holm,L. and Rosenstrom,P. (2010) Dali server: conservation mapping in 3D. *Nucleic Acids Res.*, **38**, W545–W549.
50. Wright,J.D., Mace,P.D. and Day,C.L. (2016) Secondary ubiquitin-RING docking enhances Arkadia and Ark2C E3 ligase activity. *Nat. Struct. Mol. Biol.*, **23**, 45–52.
51. Krishna,S.S., Majumdar,I. and Grishin,N.V. (2003) Structural classification of zinc fingers: survey and summary. *Nucleic Acids Res.*, **31**, 532–550.
52. Hubbard,S.J. and Thornton,J.M. (1993) NACCESS Computer Program, Department of Biochemistry and Molecular Biology, University College London.
53. Haddad,R., Maurice,F., Viphakone,N., Voisinnet-Hakil,F., Fribourg,S. and Minvielle-Sebastia,L. (2012) An essential role for Clp1 in assembly of polyadenylation complex CF IA and Pol II transcription termination. *Nucleic Acids Res.*, **40**, 1226–1239.
54. Bono,F., Ebert,J., Unterholzner,L., Guttler,T., Izaurrealde,E. and Conti,E. (2004) Molecular insights into the interaction of PYM with the Mago-Y14 core of the exon junction complex. *EMBO Rep.*, **5**, 304–310.
55. Johnson,S.A., Cubberley,G. and Bentley,D.L. (2009) Cotranscriptional recruitment of the mRNA export factor Yra1 by direct interaction with the 3' end processing factor Pcf11. *Mol. Cell.*, **33**, 215–226.
56. Johnson,S.A., Kim,H., Erickson,B. and Bentley,D.L. (2011) The export factor Yra1 modulates mRNA 3' end processing. *Nat. Struct. Mol. Biol.*, **18**, 1164–1171.
57. Pabo,C.O., Peisach,E. and Grant,R.A. (2001) Design and selection of novel Cys2His2 zinc finger proteins. *Annu. Rev. Biochem.*, **70**, 313–340.
58. Hector,R.E., Nykamp,K.R., Dheur,S., Anderson,J.T., Non,P.J., Urbinati,C.R., Wilson,S.M., Minvielle-Sebastia,L. and Swanson,M.S. (2002) Dual requirement for yeast hnRNP Nab2p in mRNA poly(A) tail length control and nuclear export. *EMBO J.*, **21**, 1800–1810.
59. Grant,R.P., Marshall,N.J., Yang,J.C., Fasken,M.B., Kelly,S.M., Harreman,M.T., Neuhaus,D., Corbett,A.H. and Stewart,M. (2008) Structure of the N-terminal Mip1-binding domain of the *Saccharomyces cerevisiae* mRNA-binding protein, Nab2. *J. Mol. Biol.*, **376**, 1048–1059.
60. Lee,S.D. and Moore,C.L. (2014) Efficient mRNA polyadenylation requires a ubiquitin-like domain, a zinc knuckle, and a RING finger domain, all contained in the Mpe1 protein. *Mol. Cell. Biol.*, **34**, 3955–3967.
61. Aibara,S., Gordon,J.M., Riesterer,A.S., McLaughlin,S.H. and Stewart,M. (2017) Structural basis for the dimerization of Nab2 generated by RNA binding provides insight into its contribution to both poly(A) tail length determination and transcript compaction in *Saccharomyces cerevisiae*. *Nucleic Acids Res.*, **45**, 1529–1538.
62. Tacahashi,Y., Hubner,W., Jenny,A., Minvielle-Sebastia,L. and Keller,W. (1997) The 30-kD subunit of mammalian cleavage and polyadenylation specificity factor and its yeast homolog are RNA-binding zinc finger proteins. *Genes Dev.*, **11**, 1703–1716.
63. Barabino,S.M., Hubner,W. and Moore,C.L. (2003) Functional dissection of the zinc finger and flanking domains of the Yth1 cleavage/polyadenylation factor. *Nucleic Acids Res.*, **31**, 1744–1752.
64. Kyburz,A., Sadowski,M., Dichtl,B. and Keller,W. (2003) The role of the yeast cleavage and polyadenylation factor subunit Ydh1p/Cft2p in pre-mRNA 3'-end formation. *Nucleic Acids Res.*, **31**, 3936–3945.
65. Vo,L.T., Minet,M., Schmitter,J.M., Lacroute,F. and Wyers,F. (2001) Mpe1, a zinc knuckle protein, is an essential component of yeast cleavage and polyadenylation factor required for the cleavage and polyadenylation of mRNA. *Mol. Cell. Biol.*, **21**, 8346–8356.
66. He,X., Khan,A.U., Cheng,H., Pappas,D.L. Jr, Hampsey,M. and Moore,C.L. (2003) Functional interactions between the transcription and mRNA 3' end processing machineries mediated by Ssu72 and Sub1. *Genes Dev.*, **17**, 1030–1042.
67. Skaar,D.A. and Greenleaf,A.L. (2002) The RNA polymerase II CTD kinase CTDK-I affects pre-mRNA 3' cleavage/polyadenylation through the processing component Pti1p. *Mol. Cell.*, **10**, 1429–1439.
68. Nedea,E., He,X., Kim,M., Pootoolal,J., Zhong,G., Canadien,V., Hughes,T., Buratowski,S., Moore,C.L. and Greenblatt,J. (2003) Organization and function of APT, a subcomplex of the yeast cleavage and polyadenylation factor involved in the formation of mRNA and small nucleolar RNA 3'-ends. *J. Biol. Chem.*, **278**, 33000–33010.
69. Dichtl,B., Aasland,R. and Keller,W. (2004) Functions for *S. cerevisiae* Swd2p in 3' end formation of specific mRNAs and snoRNAs and global histone 3 lysine 4 methylation. *RNA*, **10**, 965–977.
70. Cheng,H., He,X. and Moore,C. (2004) The essential WD repeat protein Swd2 has dual functions in RNA polymerase II transcription termination and lysine 4 methylation of histone H3. *Mol. Cell. Biol.*, **24**, 2932–2943.
71. Bhattacharya,A., Tejero,R. and Montelione,G.T. (2007) Evaluating protein structures determined by structural genomics consortia. *Proteins*, **66**, 778–795.
72. Laskowski,R.A., Moss,D.S. and Thornton,J.M. (1993) Main-chain bond lengths and bond angles in protein structures. *J. Mol. Biol.*, **231**, 1049–1067.